Overview
Small cell lung cancer (SCLC) remains a challenging disease to treat, especially following relapse. However, new treatment options and potential biomarkers have emerged, including a role for immunotherapy in this disease. In this presentation, Dr. Byers will provide a comprehensive review of the evolving landscape of SCLC treatment - with a focus on the management of patients with recurrent disease.
GOAL & PURPOSE:
- Identify and discuss recent data and current clinical research evaluating the efficacy and safety of immunotherapeutic agents in the treatment of recurrent SCLC.
- Assess those clinical research findings that are most relevant to treating clinicians.
- Appraise the utility of immunotherapy in the management of recurrent SCLC and its evolutionary role in current treatment algorithms.
After attending this webinar, learners will:
- Provide a comprehensive review of the current treatment landscape for recurrent small cell lung cancer (SCLC).
- Update scientific progress in the discovery and use of new biomarkers.
- Appraise the clinical role for immunotherapy in the treatment of recurrent SCLC.
- Discuss the incorporation of immunotherapy into treatment paradigms.
- Identify ongoing clinical trials that are likely to impact patient care in the near future.
Lauren Averett Byers, MD
Associate Professor, Department of Thoracic/Head and Neck Medical Oncology, MD Anderson Cancer Center, Houston Texas.
Ramaswamy Govindan, MD - Program Chair
Director, Section of Medical Oncology, Professor of Medicine, Anheuser-Busch Endowed Chair in Medical Oncology, Director, Section of Oncology, Washington University School of Medicine.
For any inquiries, please contact meetings@iaslc.org.
After attending this webinar, learners will:
- Provide a comprehensive review of the current treatment landscape for recurrent small cell lung cancer (SCLC).
- Update scientific progress in the discovery and use of new biomarkers.
- Appraise the clinical role for immunotherapy in the treatment of recurrent SCLC.
- Discuss the incorporation of immunotherapy into treatment paradigms.
- Identify ongoing clinical trials that are likely to impact patient care in the near future.
Lauren Averett Byers, MD
Associate Professor, Department of Thoracic/Head and Neck Medical Oncology, MD Anderson Cancer Center, Houston Texas.
Ramaswamy Govindan, MD - Program Chair
Director, Section of Medical Oncology, Professor of Medicine, Anheuser-Busch Endowed Chair in Medical Oncology, Director, Section of Oncology, Washington University School of Medicine.
For any inquiries, please contact meetings@iaslc.org.